Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma-Reference-Cited by-同舟云学术

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma

Published:2021-09-08 Issue:20 Volume:10 Page:6933-6936
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Foureau David¹^ORCID,Bhutani Manisha²,Guo Fei¹,Rigby Katherine²,Leonidas Marina¹,Tjaden Elise²,Fox Andee²,Atrash Shebli²,Paul Barry²,Voorhees Peter M.²^ORCID,Usmani Saad Z.²

Affiliation:

1. Immune Monitoring Core Laboratory Levine Cancer InstituteAtrium Health Charlotte North Carolina USA

2. Department of Hematologic Oncology Levine Cancer InstituteAtrium Health Charlotte North Carolina USA

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4254

Reference6 articles.

1. Identification of low level monoclonality using quantitative immunoprecipitation mass spectrometry (QIP-MS) as a first line monoclonal gammopathy screening strategy

2. A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis

3. Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal Gammopathy

4. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

5. Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid chromatography-tandem mass spectrometry in clinical laboratory protein measurement;Clinica Chimica Acta;2024-08

2. M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma;Clinica Chimica Acta;2024-01

3. Aiming for the cure in myeloma: Putting our best foot forward;Blood Reviews;2023-11

4. Measurable residual disease in peripheral blood in myeloma: dream or reality;Current Opinion in Oncology;2023-08-13

5. Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma;Leukemia & Lymphoma;2023-04-25